Endocrine-Disrupting Chemicals and Female Reproductive Aging

Abstract

Female reproductive aging often affects women's emotional, physical, and physiological well-being. Ovarian aging is characterized by fluctuations in reproductive hormones and determines the age at which menopause occurs. Understanding potentially modifiable factors that influence this process is essential for addressing health disparities, improving quality of life, and informing relevant public health strategies. This review synthesizes in vivo, in vitro, and epidemiological findings about the effects of endocrine-disrupting chemicals (EDCs), specifically heavy metals and perfluoroalkyl and polyfluoroalkyl substances (PFAS) on female reproductive aging. Most in vivo and in vitro studies have demonstrated that heavy metals alter ovarian morphology, folliculogenesis, and steroidogenesis. Evidence regarding the effects of PFAS is limited and inconsistent. Epidemiological studies have consistently shown that heavy metals are associated with a higher risk of diminished ovarian reserve (indicated by decreased anti-Müllerian hormone) and earlier menopause, with limited findings regarding reproductive hormone changes. PFAS exposure has been associated with decreased estradiol and earlier menopause but not significantly with ovarian reserve. Gaps in the literature require more comprehensive epidemiological research on the effects of EDCs on female reproductive aging, including ovarian reserve, age at menopause, and vasomotor symptoms, to inform future interventions to reduce hazardous exposures and improve women's health.

Keywords

endocrine-disrupting chemicals - perfluoroalkyl and polyfluoroalkyl substances - heavy metals - female reproductive aging - menopause

Publikationsverlauf

Artikel online veröffentlicht:
29. Januar 2025

• References

• 1 Zoeller RT, Brown TR, Doan LL. et al. Endocrine-disrupting chemicals and public health protection: a statement of principles from The Endocrine Society. Endocrinology 2012; 153 (09) 4097-4110
• 2 Diamanti-Kandarakis E, Bourguignon JP, Giudice LC. et al. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev 2009; 30 (04) 293-342
• 3 Padmanabhan V, Song W, Puttabyatappa M. Praegnatio perturbatio-impact of endocrine-disrupting chemicals. Endocr Rev 2021; 42 (03) 295-353
• 4 10 chemicals of public health concern. Accessed June 22, 2024 at: https://www.who.int/news-room/photo-story/photo-story-detail/10-chemicals-of-public-health-concern
• 5 Substance Priority List | ATSDR. October 18, 2023 . Accessed October 29, 2024 at: https://www.atsdr.cdc.gov/spl/index.html
• 6 Attina TM, Hauser R, Sathyanarayana S. et al. Exposure to endocrine-disrupting chemicals in the USA: a population-based disease burden and cost analysis. Lancet Diabetes Endocrinol 2016; 4 (12) 996-1003
• 7 Kahn LG, Philippat C, Nakayama SF, Slama R, Trasande L. Endocrine-disrupting chemicals: implications for human health. Lancet Diabetes Endocrinol 2020; 8 (08) 703-718
• 8 Vandenberg LN, Colborn T, Hayes TB. et al. Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. Endocr Rev 2012; 33 (03) 378-455
• 9 Vandenberg LN. Non-monotonic dose responses in studies of endocrine disrupting chemicals: bisphenol a as a case study. Dose Response 2013; 12 (02) 259-276
• 10 Birnbaum LS. Environmental chemicals: evaluating low-dose effects. Environ Health Perspect 2012; 120 (04) A143-A144
• 11 Bao S, Yin T, Liu S. Ovarian aging: energy metabolism of oocytes. J Ovarian Res 2024; 17 (01) 118
• 12 Harlow SD, Gass M, Hall JE. et al; STRAW + 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 2012; 97 (04) 1159-1168
• 13 Tanbo TG, Fedorcsak PZ. Can time to menopause be predicted?. Acta Obstet Gynecol Scand 2021; 100 (11) 1961-1968
• 14 Crandall CJ, Mehta JM, Manson JE. Management of menopausal symptoms: a review. JAMA 2023; 329 (05) 405-420
• 15 Hall JE. Endocrinology of the menopause. Endocrinol Metab Clin North Am 2015; 44 (03) 485-496
• 16 Deecher DC, Dorries K. Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages. Arch Womens Ment Health 2007; 10 (06) 247-257
• 17 Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 2005; 3: 47
• 18 Tandon VR, Sharma S, Mahajan A, Mahajan A, Tandon A. Menopause and sleep disorders. J Midlife Health 2022; 13 (01) 26-33
• 19 Baker FC, Lampio L, Saaresranta T, Polo-Kantola P. Sleep and sleep disorders in the menopausal transition. Sleep Med Clin 2018; 13 (03) 443-456
• 20 Bromberger JT, Kravitz HM, Chang Y. et al. Does risk for anxiety increase during the menopausal transition? Study of Women's Health Across the Nation. Menopause 2013; 20 (05) 488-495
• 21 Bromberger JT, Kravitz HM, Chang YF, Cyranowski JM, Brown C, Matthews KA. Major depression during and after the menopausal transition: Study of Women's Health Across the Nation (SWAN). Psychol Med 2011; 41 (09) 1879-1888
• 22 Bromberger JT, Schott LL, Kravitz HM. et al. Longitudinal change in reproductive hormones and depressive symptoms across the menopausal transition: results from the Study of Women's Health Across the Nation (SWAN). Arch Gen Psychiatry 2010; 67 (06) 598-607
• 23 Waetjen LE, Crawford SL, Chang PY. et al; Study of Women's Health Across the Nation (SWAN). Factors associated with developing vaginal dryness symptoms in women transitioning through menopause: a longitudinal study. Menopause 2018; 25 (10) 1094-1104
• 24 Ji MX, Yu Q. Primary osteoporosis in postmenopausal women. Chronic Dis Transl Med 2015; 1 (01) 9-13
• 25 de Villiers TJ. Bone health and menopause: osteoporosis prevention and treatment. Best Pract Res Clin Endocrinol Metab 2024; 38 (01) 101782
• 26 El Khoudary SR, Aggarwal B, Beckie TM. et al; American Heart Association Prevention Science Committee of the Council on Epidemiology and Prevention; and Council on Cardiovascular and Stroke Nursing. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation 2020; 142 (25) e506-e532
• 27 Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol 2012; 13 (11) 1141-1151
• 28 de Graaff J, Stolte LA. Age at menarche and menopause of uterine cancer patients. Eur J Obstet Gynecol Reprod Biol 1978; 8 (04) 187-193
• 29 Ossewaarde ME, Bots ML, Verbeek ALM. et al. Age at menopause, cause-specific mortality and total life expectancy. Epidemiology 2005; 16 (04) 556-562
• 30 Franceschi S, La Vecchia C, Booth M. et al. Pooled analysis of 3 European case-control studies of ovarian cancer: II. Age at menarche and at menopause. Int J Cancer 1991; 49 (01) 57-60
• 31 Ding N, Harlow SD, Randolph Jr JF, Loch-Caruso R, Park SK. Perfluoroalkyl and polyfluoroalkyl substances (PFAS) and their effects on the ovary. Hum Reprod Update 2020; 26 (05) 724-752
• 32 Levine L, Hall JE. Does the environment affect menopause? A review of the effects of endocrine disrupting chemicals on menopause. Climacteric 2023; 26 (03) 206-215
• 33 Ding T, Yan W, Zhou T. et al. Endocrine disrupting chemicals impact on ovarian aging: evidence from epidemiological and experimental evidence. Environ Pollut 2022; 305: 119269
• 34 FAO. Weltgesundheitsorganisation, Internationale Atomenergie-Organisation, eds. Trace Elements in Human Nutrition and Health. World Health Organization; 1996
• 35 Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS). National Institute of Environmental Health Sciences. Accessed June 22, 2024 at: https://www.niehs.nih.gov/health/topics/agents/pfc
• 36 Martinez-Morata I, Sobel M, Tellez-Plaza M, Navas-Acien A, Howe CG, Sanchez TR. A state-of-the-science review on metal biomarkers. Curr Environ Health Rep 2023; 10 (03) 215-249
• 37 Gulson BL, Cameron MA, Smith AJ. et al. Blood lead-urine lead relationships in adults and children. Environ Res 1998; 78 (02) 152-160
• 38 Sommar JN, Hedmer M, Lundh T, Nilsson L, Skerfving S, Bergdahl IA. Investigation of lead concentrations in whole blood, plasma and urine as biomarkers for biological monitoring of lead exposure. J Expo Sci Environ Epidemiol 2014; 24 (01) 51-57
• 39 Forsthuber M, Kaiser AM, Granitzer S. et al. Albumin is the major carrier protein for PFOS, PFOA, PFHxS, PFNA and PFDA in human plasma. Environ Int 2020; 137: 105324
• 40 Carignan CC, Bauer RA, Patterson A. et al. Self-collection blood test for PFASs: comparing volumetric microsamplers with a traditional serum approach. Environ Sci Technol 2023; 57 (21) 7950-7957
• 41 Malecki KMC, Andersen JK, Geller AM. et al. Integrating environment and aging research: opportunities for synergy and acceleration. Front Aging Neurosci 2022; 14: 824921
• 42 Risher JF, Todd GD, Meyer D, Zunker CL. The elderly as a sensitive population in environmental exposures: making the case. Rev Environ Contam Toxicol 2010; 207: 95-157
• 43 Vig EK, Hu H. Lead toxicity in older adults. J Am Geriatr Soc 2000; 48 (11) 1501-1506
• 44 Morello-Frosch R, Zuk M, Jerrett M, Shamasunder B, Kyle AD. Understanding the cumulative impacts of inequalities in environmental health: implications for policy. Health Aff (Millwood) 2011; 30 (05) 879-887
• 45 Schnake-Mahl AS, Lazo M, Dureja K, Ehtesham N, Bilal U. Racial and ethnic inequities in occupational exposure across and between US cities. SSM Popul Health 2021; 16: 100959
• 46 Manocha A, Srivastava LM, Bhargava S. Lead as a risk factor for osteoporosis in post-menopausal women. Indian J Clin Biochem 2017; 32 (03) 261-265
• 47 Emmanuelle NE, Marie-Cécile V, Florence T. et al. Critical role of estrogens on bone homeostasis in both male and female: from physiology to medical implications. Int J Mol Sci 2021; 22 (04) 1568
• 48 Wong F, MacLeod M, Mueller JF, Cousins IT. Enhanced elimination of perfluorooctane sulfonic acid by menstruating women: evidence from population-based pharmacokinetic modeling. Environ Sci Technol 2014; 48 (15) 8807-8814
• 49 US EPA O. National Primary Drinking Water Regulations. Published November 30, 2015. Accessed June 23, 2024 at: https://www.epa.gov/ground-water-and-drinking-water/national-primary-drinking-water-regulations
• 50 Nutrition C for FS and A. Environmental Contaminants in Food. FDA. Published January 17, 2024. Accessed June 23, 2024 at: https://www.fda.gov/food/chemical-contaminants-pesticides/environmental-contaminants-food
• 51 1910 | Occupational Safety and Health Administration. Accessed June 23, 2024 at: https://www.osha.gov/laws-regs/regulations/standardnumber/1910
• 52 Legislation - European Commission. Accessed June 23, 2024 at: https://food.ec.europa.eu/safety/chemical-safety/contaminants/legislation_en
• 53 Dumitrescu E, Chiurciu V, Muselin F. et al. Effects of long-term exposure of female rats to low levels of lead: ovary and uterus histological architecture changes. Turk J Biol 2015; 39 (02) 284-289
• 54 Dhir V, Dhand P. Toxicological approach in chronic exposure to lead on reproductive functions in female rats (Rattus norvegicus). Toxicol Int 2010; 17 (01) 1-7
• 55 Jiang X, Xing X, Zhang Y. et al. Lead exposure activates the Nrf2/Keap1 pathway, aggravates oxidative stress, and induces reproductive damage in female mice. Ecotoxicol Environ Saf 2021; 207: 111231
• 56 Osowski A, Fedoniuk L, Bilyk Y. et al. Lead exposure assessment and its impact on the structural organization and morphological peculiarities of rat ovaries. Toxics 2023; 11 (09) 769
• 57 Dumitrescu E, Cristina R, Muselin F. Reproductive biology study of dynamics of female sexual hormones: a 12-month exposure to lead acetate rat model. Turk J Biol 2014; 38 (05) 581-585
• 58 Nasiadek M, Danilewicz M, Klimczak M, Stragierowicz J, Kilanowicz A. Subchronic exposure to cadmium causes persistent changes in the reproductive system in female Wistar rats. Oxid Med Cell Longev 2019; 2019: 6490820
• 59 Chen N, Luo L, Zhang C. et al. Anti-Müllerian hormone participates in ovarian granulosa cell damage due to cadmium exposure by negatively regulating stem cell factor. Reprod Toxicol 2020; 93: 54-60
• 60 da Costa CS, Oliveira TF, Freitas-Lima LC. et al. Subacute cadmium exposure disrupts the hypothalamic-pituitary-gonadal axis, leading to polycystic ovarian syndrome and premature ovarian failure features in female rats. Environ Pollut 2021; 269: 116154
• 61 Wang C, Ma W, Su Y. NF-κB pathway contributes to cadmium-induced apoptosis of porcine granulosa cells. Biol Trace Elem Res 2013; 153 (1-3): 403-410
• 62 Ruslee SS, Zaid SSM, Bakrin IH, Goh YM, Mustapha NM. Protective effect of Tualang honey against cadmium-induced morphological abnormalities and oxidative stress in the ovary of rats. BMC Complement Med Ther 2020; 20 (01) 160
• 63 Zhong P, Liu J, Li H. et al. MicroRNA-204-5p regulates apoptosis by targeting Bcl2 in rat ovarian granulosa cells exposed to cadmium†. Biol Reprod 2020; 103 (03) 608-619
• 64 Dong F, Li J, Lei WL. et al. Chronic cadmium exposure causes oocyte meiotic arrest by disrupting spindle assembly checkpoint and maturation promoting factor. Reprod Toxicol 2020; 96: 141-149
• 65 Altunkaynak BZ, Akgül N, Yahyazadeh A. et al. Effect of mercury vapor inhalation on rat ovary: stereology and histopathology. J Obstet Gynaecol Res 2016; 42 (04) 410-416
• 66 Merlo E, Schereider IRG, Simões MR, Vassallo DV, Graceli JB. Mercury leads to features of polycystic ovary syndrome in rats. Toxicol Lett 2019; 312: 45-54
• 67 Mondal S, Mukherjee S, Chaudhuri K, Kabir SN, Kumar Mukhopadhyay P. Prevention of arsenic-mediated reproductive toxicity in adult female rats by high protein diet. Pharm Biol 2013; 51 (11) 1363-1371
• 68 Dash M, Maity M, Dey A. et al. The consequence of NAC on sodium arsenite-induced uterine oxidative stress. Toxicol Rep 2018; 5: 278-287
• 69 Chen Y, Sun Y, Zhao A. et al. Arsenic exposure diminishes ovarian follicular reserve and induces abnormal steroidogenesis by DNA methylation. Ecotoxicol Environ Saf 2022; 241: 113816
• 70 Elshawarby AM, Saleh HA, Attia AAEM, Negm EA. Arsenic-induced toxicity in the endometrium of adult albino rat and the possible role of human chorionic gonadotropin hormone: a histological study. Egypt J Histol 2014; 37 (02) 327
• 71 Mehta M, Hundal SS. Effect of sodium arsenite on reproductive organs of female Wistar rats. Arch Environ Occup Health 2016; 71 (01) 16-25
• 72 Nandheeswari K, Jayapradha P, Nalla SV, Dubey I, Kushwaha S. Arsenic-induced thyroid hormonal alterations and their putative influence on ovarian follicles in Balb/c mice. Biol Trace Elem Res Published online December 14, 2023
• 73 Du G, Huang H, Hu J. et al. Endocrine-related effects of perfluorooctanoic acid (PFOA) in zebrafish, H295R steroidogenesis and receptor reporter gene assays. Chemosphere 2013; 91 (08) 1099-1106
• 74 Yang M, Lee Y, Gao L. et al. Perfluorooctanoic acid disrupts ovarian steroidogenesis and folliculogenesis in adult mice. Toxicol Sci 2022; 186 (02) 260-268
• 75 Du G, Hu J, Huang H. et al. Perfluorooctane sulfonate (PFOS) affects hormone receptor activity, steroidogenesis, and expression of endocrine-related genes in vitro and in vivo. Environ Toxicol Chem 2013; 32 (02) 353-360
• 76 Feng X, Wang X, Cao X, Xia Y, Zhou R, Chen L. Chronic exposure of female mice to an environmental level of perfluorooctane sulfonate suppresses estrogen synthesis through reduced histone H3K14 acetylation of the StAR promoter leading to deficits in follicular development and ovulation. Toxicol Sci 2015; 148 (02) 368-379
• 77 Park SU, Walsh L, Berkowitz KM. Mechanisms of ovarian aging. Reproduction 2021; 162 (02) R19-R33
• 78 Alammari R, Lightfoot M, Hur HC. Impact of cystectomy on ovarian reserve: review of the literature. J Minim Invasive Gynecol 2017; 24 (02) 247-257
• 79 de Vet A, Laven JSE, de Jong FH, Themmen APN, Fauser BCJM. Antimüllerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 2002; 77 (02) 357-362
• 80 Moolhuijsen LME, Visser JA. Anti-Müllerian hormone and ovarian reserve: update on assessing ovarian function. J Clin Endocrinol Metab 2020; 105 (11) 3361-3373
• 81 Fauser BCJM, Nelson SM. Next steps toward AMH as a robust biomarker for assessing ovarian aging in individual women. J Clin Endocrinol Metab 2020; 105 (07) e2643-e2644
• 82 Génard-Walton M, Warembourg C, Duros S. et al. Heavy metals and diminished ovarian reserve: single-exposure and mixture analyses amongst women consulting in French fertility centres. Reprod Biomed Online 2023; 47 (03) 103241
• 83 Ding N, Wang X, Harlow SD, Randolph Jr JF, Gold EB, Park SK. Heavy metals and trajectories of anti-Müllerian hormone during the menopausal transition. J Clin Endocrinol Metab 2024; 109 (11) e2057-e2064
• 84 Upson K, O'Brien KM, Hall JE, Tokar EJ, Baird DD. Cadmium exposure and ovarian reserve in women aged 35-49 years: the impact on results from the creatinine adjustment approach used to correct for urinary dilution. Am J Epidemiol 2021; 190 (01) 116-124
• 85 Lee YM, Chung HW, Jeong K. et al. Association between cadmium and anti-Mullerian hormone in premenopausal women at particular ages. Ann Occup Environ Med 2018; 30: 44
• 86 Crawford NM, Fenton SE, Strynar M, Hines EP, Pritchard DA, Steiner AZ. Effects of perfluorinated chemicals on thyroid function, markers of ovarian reserve, and natural fertility. Reprod Toxicol 2017; 69: 53-59
• 87 Wise LA, Wang TR, Mikkelsen EM. et al. Per- and polyfluoroalkyl substances and anti-Müllerian hormone concentrations in two preconception cohort studies. Environ Health Perspect 2023; 131 (10) 107703
• 88 Tian T, Hao Y, Wang Y. et al. Mixed and single effects of endocrine disrupting chemicals in follicular fluid on likelihood of diminished ovarian reserve: a case-control study. Chemosphere 2023; 330: 138727
• 89 Krieg Jr EF, Feng HA. The relationships between blood lead levels and serum follicle stimulating hormone and luteinizing hormone in the National Health and Nutrition Examination Survey 1999-2002. Reprod Toxicol 2011; 32 (03) 277-285
• 90 Tong H, Su B, Liu Z, Chen Y. Follicle-stimulating hormone and blood lead levels with bone mineral density and the risk of fractures in pre- and postmenopausal women. Front Endocrinol (Lausanne) 2022; 13: 1054048
• 91 Wang X, Ding N, Harlow SD. et al. Exposure to heavy metals and hormone levels in midlife women: the Study of Women's Health Across the Nation (SWAN). Environ Pollut 2023; 317: 120740
• 92 Pollack AZ, Schisterman EF, Goldman LR. et al. Cadmium, lead, and mercury in relation to reproductive hormones and anovulation in premenopausal women. Environ Health Perspect 2011; 119 (08) 1156-1161
• 93 Nagata C, Konishi K, Goto Y. et al. Associations of urinary cadmium with circulating sex hormone levels in pre- and postmenopausal Japanese women. Environ Res 2016; 150: 82-87
• 94 Knox SS, Jackson T, Javins B, Frisbee SJ, Shankar A, Ducatman AM. Implications of early menopause in women exposed to perfluorocarbons. J Clin Endocrinol Metab 2011; 96 (06) 1747-1753
• 95 Barrett ES, Chen C, Thurston SW. et al. Perfluoroalkyl substances and ovarian hormone concentrations in naturally cycling women. Fertil Steril 2015; 103 (05) 1261-70.e3
• 96 Tsai MS, Lin CY, Lin CC. et al. Association between perfluoroalkyl substances and reproductive hormones in adolescents and young adults. Int J Hyg Environ Health 2015; 218 (05) 437-443
• 97 Harlow SD, Hood MM, Ding N. et al. Per- and polyfluoroalkyl substances and hormone levels during the menopausal transition. J Clin Endocrinol Metab 2021; 106 (11) e4427-e4437
• 98 Mendola P, Brett K, Dibari JN, Pollack AZ, Tandon R, Shenassa ED. Menopause and lead body burden among US women aged 45-55, NHANES 1999-2010. Environ Res 2013; 121: 110-113
• 99 Gonzalez-Martin R, Grau-Perez M, Sebastian-Leon P. et al. Association of blood cadmium and lead levels with self-reported reproductive lifespan and pregnancy loss: the national health and nutrition examination survey 1999-2018. Environ Res 2023; 233: 116514
• 100 Silbergeld EK, Schwartz J, Mahaffey K. Lead and osteoporosis: mobilization of lead from bone in postmenopausal women. Environ Res 1988; 47 (01) 79-94
• 101 Nash D, Magder LS, Sherwin R, Rubin RJ, Silbergeld EK. Bone density-related predictors of blood lead level among peri- and postmenopausal women in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2004; 160 (09) 901-911
• 102 Eum KD, Weisskopf MG, Nie LH, Hu H, Korrick SA. Cumulative lead exposure and age at menopause in the Nurses' Health Study cohort. Environ Health Perspect 2014; 122 (03) 229-234
• 103 Wang X, Ding N, Harlow SD. et al. Urinary metals and metal mixtures and timing of natural menopause in midlife women: The Study of Women's Health Across the Nation. Environ Int 2021; 157: 106781
• 104 Yunus FM, Rahman MJ, Alam MZ, Hore SK, Rahman M. Relationship between arsenic skin lesions and the age of natural menopause. BMC Public Health 2014; 14: 419
• 105 Taylor KW, Hoffman K, Thayer KA, Daniels JL. Polyfluoroalkyl chemicals and menopause among women 20-65 years of age (NHANES). Environ Health Perspect 2014; 122 (02) 145-150
• 106 Dhingra R, Darrow LA, Klein M, Winquist A, Steenland K. Perfluorooctanoic acid exposure and natural menopause: a longitudinal study in a community cohort. Environ Res 2016; 146: 323-330
• 107 Ding N, Harlow SD, Randolph JF. et al. Associations of perfluoroalkyl substances with incident natural menopause: the Study of Women's Health Across the Nation. J Clin Endocrinol Metab 2020; 105 (09) e3169-e3182
• 108 Vollenhoven B, Hunt S. Ovarian ageing and the impact on female fertility. F1000Research 2018; 7
• 109 Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr Rev 2009; 30 (05) 465-493
• 110 Wang X, Wang L, Xiang W. Mechanisms of ovarian aging in women: a review. J Ovarian Res 2023; 16 (01) 67
• 111 Gao X, Wang B, Huang Y. et al. Role of the Nrf2 signaling pathway in ovarian aging: potential mechanism and protective strategies. Int J Mol Sci 2023; 24 (17) 13327
• 112 Yan F, Zhao Q, Li Y. et al. The role of oxidative stress in ovarian aging: a review. J Ovarian Res 2022; 15 (01) 100
• 113 Ma Q. Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol 2013; 53: 401-426
• 114 Lee DY, Song MY, Kim EH. Role of oxidative stress and Nrf2/KEAP1 signaling in colorectal cancer: mechanisms and therapeutic perspectives with phytochemicals. Antioxidants 2021; 10 (05) 743
• 115 Klein CE. The hypothalamic-pituitary-gonadal axis. In: Holland-Frei Cancer Medicine. 6th Edition.. BC Decker; 2003. . Accessed July 19, 2024 at: https://www.ncbi.nlm.nih.gov/books/NBK13386/
• 116 Sauer JM, Stine ER, Gunawardhana L, Hill DA, Sipes IG. The Liver as a Target for Chemical-Chemical Interactions. In: Li AP. ed. Advances in Pharmacology. Vol 43. Academic Press; 1997: 37-63
• 117 Palmisano BT, Zhu L, Stafford JM. Role of estrogens in the regulation of liver lipid metabolism. Adv Exp Med Biol 2017; 1043: 227-256
• 118 Kang H, Ding N, Karvonen-Gutierrez CA, Mukherjee B, Calafat AM, Park SK. Per- and polyfluoroalkyl substances (PFAS) and lipid trajectories in women 45-56 years of age: the Study of Women's Health Across the Nation. Environ Health Perspect 2023; 131 (08) 87004
• 119 Anderson DC. Sex-hormone-binding globulin. Clin Endocrinol (Oxf) 1974; 3 (01) 69-96
• 120 Hammond GL, Bocchinfuso WP. Sex hormone-binding globulin: gene organization and structure/function analyses. Horm Res 1996; 45 (3-5): 197-201
• 121 Caldwell JD, Jirikowski GF. Sex hormone binding globulin and aging. Horm Metab Res 2009; 41 (03) 173-182
• 122 Gold EB, Colvin A, Avis N. et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: Study of Women's Health Across the Nation. Am J Public Health 2006; 96 (07) 1226-1235
• 123 Thurston RC, Joffe H. Vasomotor symptoms and menopause: findings from the Study of Women's Health across the Nation. Obstet Gynecol Clin North Am 2011; 38 (03) 489-501
• 124 Avis NE, Crawford SL, Greendale G. et al; Study of Women's Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015; 175 (04) 531-539
• 125 Babadi RS, Williams PL, Li Z. et al. Urinary phthalate metabolite concentrations and hot flash outcomes: longitudinal associations in the Midlife Women's Health Study. Environ Res 2023; 216 (Pt 2): 114576
• 126 Ziv-Gal A, Gallicchio L, Chiang C. et al. Phthalate metabolite levels and menopausal hot flashes in midlife women. Reprod Toxicol 2016; 60: 76-81
• 127 Hodis HN, Collins P, Mack WJ, Schierbeck LL. The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric 2012; 15 (03) 217-228
• 128 Davidson S, Jahnke S, Jung AM. et al. Anti-Müllerian hormone levels among female firefighters. Int J Environ Res Public Health 2022; 19 (10) 5981
• 129 Barzen-Hanson KA, Roberts SC, Choyke S. et al. Discovery of 40 classes of per- and polyfluoroalkyl substances in historical aqueous film-forming foams (AFFFs) and AFFF-impacted groundwater. Environ Sci Technol 2017; 51 (04) 2047-2057